Sign in
CompletedPhase 4

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

Key facts

Who runs it
MetroHealth Medical Center
Where
Cleveland, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
26 people enrolled
Started
14 Mar 2022
Ended
31 Mar 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Gabapentin
  • Placebo
Record updated
1 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Traumatic SCI
  • All levels of SCI
  • All severities of SCI, AIS A-D
  • Age 18 years and older
  • Agree to participate and start study drug within 120 hours' post-injury
  • Adequate cognition and communication to provide informed consent

Who cannot take part

  • Presence of moderate/severe traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) < 13 at 120 hours' post-injury
  • Documented use of gabapentinoids at the time of injury

Where in United States

  • MetroHealth Medical CenterCleveland, United States

About the trial

What the trial wants to find out

The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.

The 3 groups in the trial

  • Low doseTreatment being tested

    600mg treatment group will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.

    Treatment: Gabapentin

  • Medium doseTreatment being tested

    1800 mg treatment groups will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.

    Treatment: Gabapentin

  • ControlPlacebo, for comparison

    The control group will receive 2 placebo capsules of inert cellulose by mouth 3 times per day for 90 days.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
1 October 2026